Miglitol

CAT:
804-HY-B0481-01
Size:
500 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Miglitol - image 1

Miglitol

  • UNSPSC Description:

    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets[1][2][3][4].
  • Target Antigen:

    AMPK; Glycosidase; Reactive Oxygen Species
  • Type:

    Reference compound
  • Related Pathways:

    Epigenetics;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB;PI3K/Akt/mTOR
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Metabolic Disease
  • Assay Protocol:

    https://www.medchemexpress.com/Miglitol.html
  • Purity:

    98.0
  • Solubility:

    H2O : ≥ 200 mg/mL
  • Smiles:

    O[C@@H]1[C@@H](CO)N(CCO)C[C@H](O)[C@H]1O
  • Molecular Weight:

    207.22
  • References & Citations:

    [1]Fukaya, N., et al., The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol, 2009. 624(1-3): p. 51-7.|[2]Hirata, A., et al., Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res, 2009. 41(3): p. 213-20.|[3]Scott LJ, et al. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000 Mar;59(3):521-49. |[4]Aoki C, et al. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. J Pharmacol Sci. 2012;120(2):121-8.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    Launched
  • CAS Number:

    72432-03-2